ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the subsidy status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the subsidy recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 May 2022
Last Updated on 02 May 2022
A- A+
Guidance Recommendations
The Ministry of Health’s MTAC has recommended subsidy for active middle ear implants (AMEI) for patients with hearing loss, including

  • Patients with conductive hearing loss (CHL) or mixed hearing loss (MHL) who fulfil the following criteria and cannot achieve success or adequate benefit from traditional therapy and external hearing aids:
    • Bilateral stable hearing loss in each ear of ≥40dB HL;
    • Normal (free of infection or tympanic retraction) middle ear;
    • Normal tympanometry;
    • No inner ear disorders;
    • An air-bone gap of ≥30 dB HL across all frequencies OR at least involving the frequencies of 500, 1000 & 2000 Hz in cases of preceding reconstructive middle ear surgery with elimination of pathology; and
    • Having contraindications or medically valid reasons for not using bone conduction hearing implants (BCHI).
  • Patients with sensorineural hearing loss (SNHL) who fulfil the following criteria and cannot achieve success or adequate benefit from traditional therapy and external hearing aids:
    • A pure tone average (PTA4) <80 dB HL;
    • Bilateral symmetrical SNHL with PTA thresholds in both ears within 20 dB HL of each other;
    • Speech perception discrimination ≥65%;
    • Normal (free of infection or tympanic retraction) middle ear;
    • Normal tympanometry;
    • No inner ear disorders; and
    • An air-bone gap of <10 dB HL across all frequencies.

Subsidy status

AMEI are recommended for subsidy for the abovementioned indication(s) and the devices listed in the Annex only.

Only unilateral AMEI will be subsidised. No subsidy will be accorded for the contralateral ear in cases of bilateral implantation or to devices and accessories that are not included in the standard packages of AMEI devices.


Active Middle Ear Implants for patients with hearing loss Active Middle Ear Implants for patients with hearing loss (Annex)